Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Expert Opinion on Drug Discovery|June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma projectLucas Moreno, Hubert Caron, Birgit Geoerger, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
A multilocus technique for risk evaluation of patients with neuroblastomaInge M Ambros, Bettina Brunner, Gerhard Aigner, et al.European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2023
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsElizabeth R Tucker, Irene Jiménez, Lindi Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation GroupInge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2021
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)Angela Bellini, Ulrike Pötschger, Virginie Bernard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C Gray, Rebekah Weston, Cormac Owens, et al.The Journal of Molecular Diagnostics : JMD|October 19, 2025
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology StudyAlexandra Saint-Charles, Julien Masliah-Planchon, Elnaz Saberi-Ansari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens, et al.Pageof 7